Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Clearmind Medicine Inc. and SciSparc Ltd. have partnered to conduct a study on the combination treatment of obesity and metabolic syndrome, using Clearmind's MEAI and SciSparc's Palmitoylethanolamide (PEA). The research agreement has been entered into with the Hebrew University of Jerusalem, led by Professor Joseph Tam. A previous pre-clinical study showed that obese animals treated with MEAI de..